{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-032831","form_type":"8-K","ticker":"OGEN","cik":"0001174940","company_name":"ORAGENICS INC","filed_at":"2024-08-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.343720+00:00","generated_at":"2026-05-31T08:48:03.580377+00:00","sec_items":["3.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Oragenics receives NYSE delisting notice for equity shortfall; ONP-002 Phase 2 trial planned Q4 2024","bullets":["NYSE American notified Oragenics it is not in compliance with Section 1003(a)(i) (stockholders' equity <$2M); compliance plan approved, deadline Oct 18, 2025.","ONP-002 cleared FDA-required cardiotoxicity and genotoxicity tests; Phase 2 trial expected to start Q4 2024 in Australia.","Improved intranasal formulation increases ONP-002 per dose by 4X; automated device prototype for use in acute concussion completed.","Closed public offering raising ~$1.1M to fund ONP-002 development and corporate needs.","Appointed Dr. Peacock as Chief Clinical Officer and Dr. Kelly as Chief Medical Officer for Phase 2 trial."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-032831","json":"https://secwatch.observer/filing/0001493152-24-032831.json","markdown":"https://secwatch.observer/filing/0001493152-24-032831.md","text":"https://secwatch.observer/filing/0001493152-24-032831.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1174940/000149315224032831/0001493152-24-032831-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1174940/000149315224032831/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:48:03.580377+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}